PT2603528T - Anticorpos glicosilados em fab - Google Patents
Anticorpos glicosilados em fabInfo
- Publication number
- PT2603528T PT2603528T PT117604157T PT11760415T PT2603528T PT 2603528 T PT2603528 T PT 2603528T PT 117604157 T PT117604157 T PT 117604157T PT 11760415 T PT11760415 T PT 11760415T PT 2603528 T PT2603528 T PT 2603528T
- Authority
- PT
- Portugal
- Prior art keywords
- fab
- glycosylated antibodies
- glycosylated
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2010004878 | 2010-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2603528T true PT2603528T (pt) | 2016-12-01 |
Family
ID=44674756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT117604157T PT2603528T (pt) | 2010-08-10 | 2011-08-10 | Anticorpos glicosilados em fab |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9359439B2 (pt) |
| EP (1) | EP2603528B1 (pt) |
| JP (2) | JP6334166B2 (pt) |
| CN (1) | CN103119064B (pt) |
| AU (1) | AU2011288464B2 (pt) |
| BR (1) | BR112013003095B1 (pt) |
| CA (1) | CA2805984C (pt) |
| DK (1) | DK2603528T3 (pt) |
| ES (1) | ES2605304T3 (pt) |
| PL (1) | PL2603528T3 (pt) |
| PT (1) | PT2603528T (pt) |
| WO (1) | WO2012020065A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9051370B2 (en) | 2010-08-10 | 2015-06-09 | Glycotope Gmbh | Humanized EGFR antibodies |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| WO2014164534A2 (en) * | 2013-03-11 | 2014-10-09 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| EA201591977A1 (ru) * | 2013-04-22 | 2016-06-30 | Гликотоп Гмбх | Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование |
| HRP20230260T1 (hr) | 2014-03-19 | 2023-04-28 | Genzyme Corporation | Glikoinženjering ciljajućih dijelova specifičan za mjesto |
| JP2017528468A (ja) * | 2014-09-10 | 2017-09-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ガラクトース操作型免疫グロブリン１抗体 |
| DK3110447T3 (da) * | 2014-09-16 | 2020-06-22 | Synermore Biologics Co Ltd | Anti-EGFR-antistof og anvendelser heraf |
| PL3204425T3 (pl) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| WO2016150845A1 (en) * | 2015-03-20 | 2016-09-29 | Ablynx Nv | Glycosylated immunoglobulin single variable domains |
| WO2017162733A1 (en) * | 2016-03-22 | 2017-09-28 | Glycotope Gmbh | Iga antibodies with enhanced stability |
| NZ756323A (en) | 2017-02-28 | 2022-07-01 | Seagen Inc | Cysteine mutated antibodies for conjugation |
| CA3082231A1 (en) * | 2017-11-09 | 2019-05-16 | National Research Council Of Canada | Antibody glycoconjugates and methods of production and use |
| WO2019219891A1 (en) | 2018-05-18 | 2019-11-21 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| GB9200415D0 (en) * | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Inactivation of cytotoxic drugs |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| JP2005503789A (ja) * | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Ａβ抗体 |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| AU2004264265C1 (en) | 2003-08-14 | 2012-06-28 | Thrombogenics Nv | Antibodies against factor VIII with modified glycosylation in the variable region |
| US8017388B2 (en) | 2003-08-18 | 2011-09-13 | Glycotope Gmbh | Tumour cell lines and uses thereof |
| JP4913604B2 (ja) | 2004-02-13 | 2012-04-11 | グリコトープ ゲーエムベーハー | 高活性糖タンパク質−製造条件、及びその効率的製造方法 |
| US20060051353A1 (en) * | 2004-05-14 | 2006-03-09 | Jean-Frederic Colombel | Methods and compositions to evaluate antibody treatment response |
| JP5053264B2 (ja) | 2005-05-19 | 2012-10-17 | アムジェン インコーポレイテッド | 抗体の安定性を増加させるための組成物および方法 |
| CA2614046C (en) | 2005-06-30 | 2018-05-15 | Centocor, Inc. | Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof |
| GB0519398D0 (en) | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
| WO2007064957A1 (en) * | 2005-11-30 | 2007-06-07 | University Of Southern California | FCγ POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME |
| EA017622B1 (ru) * | 2006-09-10 | 2013-01-30 | Гликотоп Гмбх | Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков |
| US8450068B2 (en) * | 2007-02-16 | 2013-05-28 | University Of Virginia Patent Foundation | IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis |
| WO2009126564A1 (en) * | 2008-04-07 | 2009-10-15 | Bayer Healthcare Llc | Methods of recombinant production of glycoproteins |
| TW201006485A (en) * | 2008-06-03 | 2010-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US9051370B2 (en) * | 2010-08-10 | 2015-06-09 | Glycotope Gmbh | Humanized EGFR antibodies |
-
2011
- 2011-08-10 WO PCT/EP2011/063791 patent/WO2012020065A1/en active Application Filing
- 2011-08-10 PT PT117604157T patent/PT2603528T/pt unknown
- 2011-08-10 EP EP11760415.7A patent/EP2603528B1/en active Active
- 2011-08-10 DK DK11760415.7T patent/DK2603528T3/en active
- 2011-08-10 BR BR112013003095-0A patent/BR112013003095B1/pt active IP Right Grant
- 2011-08-10 ES ES11760415.7T patent/ES2605304T3/es active Active
- 2011-08-10 JP JP2013523612A patent/JP6334166B2/ja active Active
- 2011-08-10 PL PL11760415T patent/PL2603528T3/pl unknown
- 2011-08-10 US US13/816,390 patent/US9359439B2/en active Active
- 2011-08-10 CN CN201180039635.7A patent/CN103119064B/zh active Active
- 2011-08-10 AU AU2011288464A patent/AU2011288464B2/en active Active
- 2011-08-10 CA CA2805984A patent/CA2805984C/en active Active
-
2016
- 2016-07-29 JP JP2016149616A patent/JP2016185169A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2603528B1 (en) | 2016-10-12 |
| WO2012020065A1 (en) | 2012-02-16 |
| ES2605304T3 (es) | 2017-03-13 |
| US20130209458A1 (en) | 2013-08-15 |
| CA2805984A1 (en) | 2012-02-16 |
| JP2013535970A (ja) | 2013-09-19 |
| JP6334166B2 (ja) | 2018-05-30 |
| JP2016185169A (ja) | 2016-10-27 |
| AU2011288464B2 (en) | 2015-10-29 |
| CN103119064A (zh) | 2013-05-22 |
| BR112013003095B1 (pt) | 2023-03-28 |
| BR112013003095A2 (pt) | 2016-07-05 |
| AU2011288464A1 (en) | 2013-02-14 |
| CA2805984C (en) | 2021-05-25 |
| EP2603528A1 (en) | 2013-06-19 |
| US9359439B2 (en) | 2016-06-07 |
| CN103119064B (zh) | 2018-09-04 |
| DK2603528T3 (en) | 2016-11-28 |
| PL2603528T3 (pl) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180952T1 (hr) | Anti-dll3 antitijelo | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| PT2581113T (pt) | Anticorpo anti-tim-3 | |
| ZA201701051B (en) | Neutralizing anti-ccl20 antibodies | |
| PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
| GB201103955D0 (en) | Antibodies | |
| ZA201208290B (en) | Anti-erbb3 antibodies | |
| GB201112056D0 (en) | Antibodies | |
| HK1182625A1 (en) | Bispecific antibodies | |
| IL220404A (en) | Antiseptic antibodies | |
| IL225667A0 (en) | A new antigen | |
| GB201020738D0 (en) | Antibodies | |
| HK1194388A1 (zh) | 抗缺刻蛋白 抗體 | |
| PT2603528T (pt) | Anticorpos glicosilados em fab | |
| GB201002238D0 (en) | Antibodies | |
| ZA201302459B (en) | Antibodies | |
| GB201007957D0 (en) | Antibody | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201020751D0 (en) | Antibodies | |
| GB201005062D0 (en) | Antibodies | |
| GB201017780D0 (en) | Antibody | |
| IL226635B (en) | Human anti-sod1 antibodies |